PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dextran→

Dextran PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
9004-54-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
Branched glucose polysaccharideplasma volume expander and pharmaceutical polymer
Mechanism of action
High-molecular-weight dextran acts as a colloid osmotic agent in the intravascular compartment, expanding plasma volume. Lower molecular-weight dextrans have additional effects on blood rheology and platelet/coagulation interactions.
Indications / reported uses
  • Historical use as an intravenous plasma volume expander in selected settings; use is restricted or uncommon due to anaphylaxis, renal and coagulation risks. Other dextran grades are used as excipients or in diagnostic products and should not be treated as therapeutic substitutes.

Sources: NLM MeSH — Dextran · PubMed — Dextran plasma expander safety · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dextran PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dextran Permitted Daily Exposure (PDE) report (the Dextran PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dextran Occupational Exposure Limit (OEL) report (the Dextran OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.